资源描述
2009 1210 2023 01 18 4 2020 10 16(2020 1)2020 11 5 1.3 700 469 2019 93%92%95%22 10 770 730 848 12 3+N 21 9 12 88.65%95.78%4683 606 9360 987 11687 1271 22 3 3+N 83.48%640.99/907.48/1117.30/21 9 3 1 80%3.5 7000 3.2 5000 82 22 9 84%3.3 4500 4 5600 2.7 1100 1 22H1 23.18%3.66 2 22H1 5.24 13.43%2022 1 2 3 4 5 6 1 2 3 S0360520110002 S0360520110004%()446 0.06()78,429.61 8.53()57,733.18 8.24%1M 6M 12M 2.5%2.6%-13.7%-2.1%5.2%-0.5%20230115 2023-01-16 20230113 2023-01-13-31%-20%-10%1%22/01 22/03 22/06 22/08 22/11 23/012022-01-172023-01-17 300 2009 1210 2009 1210 3.5.5.6.7 12.7.8.9.10.11.12.12.15.16.16.17.18.20 2009 1210 4 1 2020.5 2.7 3.9 4.11 5.11 6.11 7.11 8.12 9.12 10.12 11.12 12.14 13 PCI.14 14-A.15 15-A.15 16-A.15 17 A.15 18.17 19 2021.18 20 2021.18 21.19 22.19 23.19 24.19 2009 1210 5 2019 7 2020 10 16 2020 1 2020 11 5 107.5 80%1.3 700 469 2019 93%92%95%109 2 2021 1 2023 1 8 10 6 2 1 2020()100690 9.4%13300 469 96%41865 3.9%7500 549 93%247940 23.1%7500 590 92%120560 11.2%8400 645 92%51667 4.8%19250 648 97%12176 1.1%-750/統 53441 5.0%7600 755 90%59842 5.6%17100 776 95%32251 3.0%11400 776 93%統 9774 0.9%7700 798 90%2009 1210 6 1 2 3 IVUS 1-2 1 645 21 22H1 12%2 750 590 21 10%3 469 96%EXCROSSAL 20 21 2022H1 2023 1 2022 9 1 2022 11 2022 12 186.5 70%95%2020 20%3 95%90%770 730 848 14 6 A 4 B 4 C A B C 21.01%42.36%18.87%10 14 10 8 Excrossal 824 75.7%31.5%848 23.7%6.7%730 800 9%24%2009 1210 7 2 1 20163132305 680 50 730 2 20203131021 729 50 779 3 20163131174 747 48 795 4 20193131802 795 1 796 5 20203130662 750 50 800 6 20163130682 Medtronic Inc.786 20 806 7 20173131407 774 50 824 8 20223131270 789 50 839 9 20223130495 795 50 845 10 20153130608 Boston Scientific Corporation 798 48 846 11 20173130564 798 50 848 12 20163130595()()798 50 848 13 20163132140 Abbott Vascular 798 50 848 14 20223131010 798 50 848 12 3+N 12 21 5 GCLH-HD2021-1 21 7 2009 1210 8 21 9 97 93.56 3.2 88.65%95.78%4683 606()9360 987 11687 1271 80 2021 11 1 2022 10 31 71 20751 3+N 22 1 3+N 22 2 3+N 22 3 3+N 17 108.57 83.48%640.99/907.48/1117.30/1 89 20026 1 2 2022 3.66%23.18%2009 1210 9 21 6 1 21 8 2 3 21 9-3 1 90%305542-126797-142757-35988 231976 2 2022 3-4 3 1 80%3.5 7000 3.2 5000 82 44 30 14 1 22H1/2 22H1 13%3 3-7,987 15,577 6,987 13,446 4,987 980 5,799 36,341 8,106 14,998 8,006 16,044 8,206 2,263 7,199 28,469 6,896 15,364 6,290 23,905 6,730 6,648 4,599 30,933 8,000 21,138 7,900 10,372 8,110 5,056-8,506 21,318 8,500 10,965-6,990 11,425 6,346 2,058 5,480 25,901 7,521-7,527 8,309 6,628-6,715 16,600 6,706-7,289 3,843 4,914-5,233 14,873-5,519 6,114 4,160 140 5,527 7,505 9,920 10,634 8,480 10,238 2,981 4,416 14,421 2009 1210 10 7,998 1,894 3,407 530 4,995 4,129 22 5 22 7 1 22 9 2 22 9 5 14 29 872 109 90%68307 21442 3992 2315 392785 78182 32097 231289 215737 115262 1495 25221 20277 457938 10528437.5 84%1/3 3.3 4500 6 4800 4 5600 2.7 1100 260 A 16 3972 4543 571 3 2023 1 2 171 152 89%1 20 10%2 3 2009 1210 11 4 1 2022 23.18%3.66 23.83%216.29%56.82%2022 2021 0.81 4 5 6 7 2 2022 18.39%5.947.7212.5715.8719.9412.35-10%0%10%20%30%40%50%60%70%0.005.0010.0015.0020.0025.002017 2018 2019 2020 2021 2022Q1-3营业收入（亿元）同比增速（右轴）2.963.714.656.066.732.12-60%-50%-40%-30%-20%-10%0%10%20%30%40%0.001.002.003.004.005.006.007.008.002017 2018 2019 2020 2021 2022Q1-3归母净利润（亿元）同比增速（右轴）2009 1210 12 22H1 5.71 18.39%5.24 13.43%4111 121.77%454 298.25%2022 0.92%2022 8 9 10 11 22H1 1 VS 3.004.988.559.3811.087.600%10%20%30%40%50%60%70%80%0.002.004.006.008.0010.0012.002017 2018 2019 2020 2021 2022Q1-3营业收入（亿元）同比增速（右轴）0.681.062.372.833.222.100%20%40%60%80%100%120%140%0.000.501.001.502.002.503.003.502017 2018 2019 2020 2021 2022Q1-3归母净利润（亿元）同比增速（右轴）2009 1210 13 1 2 1.8 1.8 2850 A B 3 90%80 4 VS 1 2 A/B C 14 29 A B C 3 A B 40%80%-100%50%4 A B 1.3 50%5 3 2 2 84%2009 1210 14 20-30%30%20%2017 5032/21 4599/3+N A 3 80%3 4.9%1.5%0.6%66%38%43%PCI 20 96.9 21 116.4 20%12 13 PCI CCIF 4 2009 1210 15 1 90%305542 231976 A A 45917-1.5 30933 A 46%2019 28%14-A 15-A 16-A 17 A 2 Eshare 2900/1.1/4800/2009 1210 16 1.2/21 6 15 2022 2 9 16 3+N 16 57,509 8%2011 Adena Duetto Zina Halis PEEK 1-ZinaII 2 ZELIF 3-Mount CLIF 4 Duetto 5 UBE,Halis9mm Lora 20 21 2009 1210 17 84%67%22 18%19 5.2%21 9.5%22 9%18 1 PRP 22H1 PEEK PRP 2022 7 NMPA NMPA PRP 22 11 2023 1 22H1 2 3D 21 7 22 4 2009 1210 18 3D 22H1 3D 3D 22H1 The Orthopaedic Industry Annual Report 2021 2020 312 65.7%EMEA 17.9%12.9%3.5%2021 8.64 39%-&6.46 44%2.18 28%19 2021 20 21&4.49 6.46 44%1.70 2.18 28%6.19 8.64 39%51.50%20 2021 1 3.19 2 0.79 3 0.47 4 0.46 5 0.27 6 0.24 7 0.22 8 0.21 9 0.17 10 0.14 6.16 2009 1210 19 1 Elliquence 21 1.36 11%2 OEM/ODM 2019 2020 21 5198 5%3 50 21 7994 4%4 21 1%21 22 23 24 2009 1210 20 1 2 3 2009 1210 21 2020 2020 2020 2020 2020 2020 2020 2021 2022 2022 2022 2009 1210 22 010-63214682 010-63214682 010-63214682 010-63214682 010-63214682 010-63214682 010-66500808 010-66500821 010-63214682 0755-82828570 0755-83715428 0755-82871425 0755-83024576 0755-82756804 0755-82756803 0755-82871425 021-20572536 021-20572551 021-20572555 021-20572257-2552 021-20572506 021-20572585 021-20572560 021-20572509 021-20572548 021-20572573 021-20572559 021-20572559 0755-82756805 021-20572559 玙 021-25072549 0755 82756805 2009 1210 23(300)6 20%6 10%20%6-10%10%6 10%20%3-6 5%3-6-5%5%3-6 5%26 C 3A 1061 A 19 33 12 100033 518034 200120 010-66500801 0755-82027731 021-20572500 010-66500900 0755-82828562 021-20572522
展开阅读全文